Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Tafenoquine Dissolution Profiles in Healthy Subjects
NCT02751294Phase 1Completed
- Sponsor
- GSK
- Start
- May 2016
- Primary completion
- Aug 2016
- Modality
- Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tafenoquine in malaria (2 arms), sponsored by GSK. Primary endpoint: Area Under the Plasma Concentration-Time Curve. Started May 2016; status: completed.
02
Drugs
tafenoquine
03
Conditions
malaria
Beyond the preview
Go deeper on NCT02751294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02751294.